Expert Discusses GLP-1 Risks for Those with EDS 

Insight from Bernadette Riley, D.O., professor of family medicine and director of the Ehlers-Danlos Syndrome (EDS)/Hypermobility Treatment Center, is featured in a Newsweek article about the risks that GLP-1 weight-loss medications may pose for those with complex chronic conditions such as Postural Orthostatic Tachycardia Syndrome and EDS. Patients with EDS may already be more prone to digestive issues like gastroparesis, in which the stomach empties too slowly, and taking a GLP-1 medication can increase this risk. However, Riley states that it cannot be generalized how EDS patients will tolerate GLP-1s, as they will have “differing side effects, symptoms, allergies, and tolerances.”